<DOC>
	<DOC>NCT01050634</DOC>
	<brief_summary>Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire. Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane). Deeper knowledge of Adverse Events during routine administration.</brief_summary>
	<brief_title>Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Early Breast Cancer, postmenopausal, 23 yrs adjuvant tamoxifen therapy.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Switch after Tamoxifen</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Safety</keyword>
</DOC>